<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03400475</url>
  </required_header>
  <id_info>
    <org_study_id>201410714</org_study_id>
    <nct_id>NCT03400475</nct_id>
  </id_info>
  <brief_title>Use of Topical Subgingival Application of Simvastatin Gel in the Treatment of Peri-Implant Mucositis</brief_title>
  <official_title>The Use of Topical Subgingival Application of Simvastatin Gel in the Treatment of Peri-Implant Mucositis: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ahmed Mohamed Mahrous</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Greater New York Academy of Prosthodontics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>American College of Prosthodontists Education Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Iowa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to test the recently discovered anti-inflammatory action of statins on
      inflamed mucosa surrounding dental implants.

      Hypothesis: The application of 1.2% simvastatin gel will decrease peri-implant inflammation.

      The pilot study will involve 44 subjects divided into a test and control group. The test
      group shall receive topical simvastatin gel administered around the implant with a blunt
      tipped needle. The control group will receive a placebo.

      Inflammatory state shall be determined at baseline as well as follow up visits at 24 hours, 1
      week, and 1 month by clinical indices of inflammation as well as biochemical markers of
      inflammation gathered from around the implants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Following signing the consent document the following will occur:

        1. Screening Patients will complete standard medical and dental health history forms,
           followed by a study specific screening questionnaire. if the patient is deemed eligible,
           the patient will be examined clinically. The clinical examination will include
           diagnostic procedures typical of an implant recall visit. Initially, the sulcus will be
           probed with a periodontal probe; if bleeding on probing is elicited, then a radiograph
           will be made.

           The following shall be done to screen the patients:

             1. Periapical radiographs of the implant to determine bone loss, if bone loss is found
                the patient will be excluded from the study.

             2. Bleeding on probing will be assessed by using a periodontal probe passed along the
                gingival crevice, and bleeding scores will be assessed passing the probe with a
                force of 0.25 N.

             3. If a woman is of childbearing age and suspected of being pregnant, a urine
                pregnancy test shall be made at this time.

           If the patient exhibits no bleeding on probing, or signs of mesial/distal bone loss
           greater than 1mm from the accepted reference point on the implant system the patient
           will be excluded from the study.

        2. Subject allocation

           Subjects will be assigned with equal allocation into the following groups:

             1. Test group: will receive 0.1 ml prepared Simvastatin in 1.2% (W/V)
                Lecithin/isopropyl palmitate solution (Lipoil速), Poloxamer 407 gel (Polox Gel 20%速)
                applied topically into the peri-implant gingival sulcus using a plastic syringe
                with a blunt cannula.

             2. Control group: will receive a placebo of 0.1 ml 40% (W/V) Lecithin/isopropyl
                palmitate solution (Lipoil速), Poloxamer 407 gel (Polox Gel 20%速) applied topically
                into the peri implant gingival sulcus using a plastic syringe with a blunt cannula.

        3. Baseline measurements Baseline measurements will be made at least 48 hours after
           screening (allowing time for complete hemostasis of peri-implant crevicular mucosa after
           bleeding induced by probing in the screening visit).

           Following baseline measurements, Test and Control interventions will be administered.

           The baseline measurements include the following:

             1. Peri-implant crevicular fluid (PICF) collection: Each implant site will be isolated
                with cotton rolls and light air will be applied over the side to eliminate ambient
                salivary contamination of the PICF sample. Sampling will be done using paper strips
                that are inserted with cotton forceps into the gingival crevice until mild
                resistance is felt. After gingival crevicular fluid (GCF) collection, the volumes
                are immediately quantified using the Periotron 8000 instrument.

             2. Gingival Index: Using the Gingival index by Loe and Sillness 1963, the inflammatory
                state of the buccal, lingual, mesial and distal surfaces of the gingiva will be
                scored using the following score system:

                0= normal gingival without signs of inflammation, no inflammation, no bleeding

                  1. minor inflammation , slight discoloration, minor surface alterations, no
                     bleeding

                  2. moderate inflammation, redness, swelling, bleeding upon probing and under
                     pressure

                  3. strong inflammation, strong redness and swelling, tendency toward spontaneous
                     bleeding, ulcerations After a score is given to each site, the scores will be
                     summed together and divided by 4 to reach an overall score.

             3. Probing depth: Measured by a calibrated periodontal probe at 6 different locations,
                mesiobuccal, midbuccal, distobuccal, distolingual, midlingual, and mesiolingual.

        4. Administration of test and control intervention will be delivered into the peri- implant
           gingival sulcus using a plastic syringe with a blunt cannula following baseline
           measurements. 0.1ml of gel will be administered with a blunt cannula evenly distributed
           in the peri-implant sulcus. The investigator will not know whether the subject is
           receiving the active or control intervention.

        5. Recall appointments and measurements Both Test and Control subjects will be scheduled
           recall visits. Recalls will be done at 24 hours (+ or - 3 hours), 1 week (+ or - 12
           hours), and 1 month (+ or - 11 days).

           On each recall visit, the following procedures will take place:

             1. PICF collection: procedures identical to those performed on the baseline visit

             2. Gingival index recording: Identical to that performed on the baseline visit

             3. probing depth measurement : procedures identical to that performed at the baseline
                visit * these measurements will be made by a blinded investigator

        6. Cytokine analysis Due to study constraints, not all PICF samples collected from subjects
           will be analyzed in the pilot study. The samples that will be analyzed will be selected
           randomly from the study population. Cytokine samples from only 13 randomly selected
           subjects from the test group, as well as 13 randomly selected subjects from the control
           group will be analyzed. Of these randomly selected samples, only those collected at
           baseline, 24 hours, and at 1 week will be analyzed. The remaining cytokine samples will
           be evaluated as part of a later study. Cytokine quantities will be determined using; a
           commercial 22 multipixed fluorescent bead based immunoassay and luminex 100 IS
           instrument. The kit used is the MILLIPLEX map Human Cytokine/ Chemokine Magnetic Bead
           Panel- Immunology Multiplex Assay (HCYTOMAG-60K) capable of detecting IL-1Beta;,
           TNF-Alpha;, IL-6, IL-8.

      The study in total will take 1 month and 2 days. All visits will generally take 0.5-1.5
      hours. No long term follow up will be required.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 23, 2015</start_date>
  <completion_date type="Actual">October 24, 2016</completion_date>
  <primary_completion_date type="Actual">October 24, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Only the study coordinator will know whether the intervention is simvastatin or control.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Interleukin 1 B at Base to 24 Hours</measure>
    <time_frame>Baseline- 24hrs</time_frame>
    <description>Measuring the change in Cytokine levels in the peri implant crevicular fluid ( Fluid around the implant) by extracting the fluid and measuring the levels of the interlukins in the fluids in Micrograms per dicileter ( ug/dl)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Interleukin 1 B at Base to 1 Week</measure>
    <time_frame>Baseline - 1 week</time_frame>
    <description>Measuring the change in Cytokine levels in the peri implant crevicular fluid ( Fluid around the implant) by extracting the fluid and measuring the levels of the interlukins in the fluids in Micrograms per dicileter ( ug/dl)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Interleukin 1 B 24 Hours - 1 Week</measure>
    <time_frame>24 hours - 1 week</time_frame>
    <description>Measuring the change in Cytokine levels in the peri implant crevicular fluid ( Fluid around the implant) by extracting the fluid and measuring the levels of the interlukins in the fluids in Micrograms per dicileter ( ug/dl)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Interleukin 6 at Base to 24 Hours</measure>
    <time_frame>Baseline - 24 hours</time_frame>
    <description>Measuring the change in Cytokine levels in the peri implant crevicular fluid ( Fluid around the implant) by extracting the fluid and measuring the levels of the interlukins in the fluids in Micrograms per dicileter ( ug/dl)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Interleukin 6 Baseline to 1 Week</measure>
    <time_frame>Baseline - 1 week</time_frame>
    <description>Measuring the change in Cytokine levels in the peri implant crevicular fluid ( Fluid around the implant) by extracting the fluid and measuring the levels of the interlukins in the fluids in Micrograms per dicileter ( ug/dl)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Interleukin 6 24 Hours - 1 Week</measure>
    <time_frame>24 hours - 1 week</time_frame>
    <description>Measuring the change in Cytokine levels in the peri implant crevicular fluid ( Fluid around the implant) by extracting the fluid and measuring the levels of the interlukins in the fluids in Micrograms per dicileter ( ug/dl)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Interleukin 8 at Base to 24 Hours</measure>
    <time_frame>Baseline - 24 hours</time_frame>
    <description>Measuring the change in Cytokine levels in the peri implant crevicular fluid ( Fluid around the implant) by extracting the fluid and measuring the levels of the interlukins in the fluids in Micrograms per dicileter ( ug/dl)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Interleukin 8 at Base to 1 Week</measure>
    <time_frame>Baseline - 1 week</time_frame>
    <description>Measuring the change in Cytokine levels in the peri implant crevicular fluid ( Fluid around the implant) by extracting the fluid and measuring the levels of the interlukins in the fluids in Micrograms per dicileter ( ug/dl)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Interleukin 8 24 Hours to 1 Week</measure>
    <time_frame>24 hours - 1 week</time_frame>
    <description>Measuring the change in Cytokine levels in the peri implant crevicular fluid ( Fluid around the implant) by extracting the fluid and measuring the levels of the interlukins in the fluids in Micrograms per dicileter ( ug/dl)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Tumor Necrosis Factor Alpha at Base to 24 Hours</measure>
    <time_frame>Baseline- 24hrs</time_frame>
    <description>Measuring the change in Cytokine levels in the peri implant crevicular fluid ( Fluid around the implant) by extracting the fluid and measuring the levels of the interlukins in the fluids in Micrograms per dicileter ( ug/dl)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Tumor Necrosis Factor Alpha at Base to 1 Week</measure>
    <time_frame>Baseline - 1 week</time_frame>
    <description>Measuring the change in Cytokine levels in the peri implant crevicular fluid ( Fluid around the implant) by extracting the fluid and measuring the levels of the interlukins in the fluids in Micrograms per dicileter ( ug/dl)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Tumor Necrosis Factor Alpha 24 Hours to 1 Week</measure>
    <time_frame>24hrs - 1 week</time_frame>
    <description>Measuring the change in Cytokine levels in the peri implant crevicular fluid ( Fluid around the implant) by extracting the fluid and measuring the levels of the interlukins in the fluids in Micrograms per dicileter ( ug/dl)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gingival Index Level (Derived From an Average Over the 4 Implant Sites) at Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Using the Gingival index by Loe and Sillness 1963, the inflammatory state of the Buccal, Lingual, Mesial and Distal Surfaces of the gingiva will be scored using the following score system:
0= normal gingival without signs of inflammation, no inflammation, no bleeding
minor inflammation , slight discoloration, minor surface alterations, no bleeding
moderate inflammation, redness, swelling, bleeding upon probing and under pressure
strong inflammation, strong redness and swelling, tendency toward spontaneous bleeding, ulcerations After a score is given to each site the scores are summed together and divided by 4 to reach an overall score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gingival Index Level (Derived From an Average Over the 4 Implant Sites) at 24 Hours</measure>
    <time_frame>24 hours</time_frame>
    <description>Using the Gingival index by Loe and Sillness 1963, the inflammatory state of the Buccal, Lingual, Mesial and Distal Surfaces of the gingiva will be scored using the following score system:
0= normal gingival without signs of inflammation, no inflammation, no bleeding
minor inflammation , slight discoloration, minor surface alterations, no bleeding
moderate inflammation, redness, swelling, bleeding upon probing and under pressure
strong inflammation, strong redness and swelling, tendency toward spontaneous bleeding, ulcerations After a score is given to each site the scores are summed together and divided by 4 to reach an overall score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gingival Index Level (Derived From an Average Over the 4 Implant Sites) at 1 Week</measure>
    <time_frame>1 week</time_frame>
    <description>Using the Gingival index by Loe and Sillness 1963, the inflammatory state of the Buccal, Lingual, Mesial and Distal Surfaces of the gingiva will be scored using the following score system:
0= normal gingival without signs of inflammation, no inflammation, no bleeding
minor inflammation , slight discoloration, minor surface alterations, no bleeding
moderate inflammation, redness, swelling, bleeding upon probing and under pressure
strong inflammation, strong redness and swelling, tendency toward spontaneous bleeding, ulcerations After a score is given to each site the scores are summed together and divided by 4 to reach an overall score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Probing Depth Level (Averaged Over 6 Sites) at Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Depth will be measured by a calibrated periodontal probe at 6 different locations, Mesiobuccal, Mid Buccal, Distobuccal, Disto Lingual, Mid Lingual and Mesio Lingual. The longitudinal course will be characterized with respect to the categorical outcome, presence of any bleeding on probing, with initial emphasis being placed upon transition approaches, with specific attention given to shifts from clinically unacceptable to clinically acceptable designations.
probing depth is considered variable from one person to the other however a decrease or a shallower probing depth overtime is gererally seen as an improvement , thus any decrease in probing depth would be seen as signs of healing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Probing Depth Level (Averaged Over 6 Sites) at 24 Hours</measure>
    <time_frame>24 hours</time_frame>
    <description>Depth will be measured by a calibrated periodontal probe at 6 different locations, Mesiobuccal, Mid Buccal, Distobuccal, Disto Lingual, Mid Lingual and Mesio Lingual. The longitudinal course will be characterized with respect to the categorical outcome, presence of any bleeding on probing, with initial emphasis being placed upon transition approaches, with specific attention given to shifts from clinically unacceptable to clinically acceptable designations.
probing depth is considered variable from one person to the other however a decrease or a shallower probing depth overtime is gererally seen as an improvement , thus any decrease in probing depth would be seen as signs of healing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Probing Depth Level (Averaged Over 6 Sites) at 1 Week</measure>
    <time_frame>1 week</time_frame>
    <description>Depth will be measured by a calibrated periodontal probe at 6 different locations, Mesiobuccal, Mid Buccal, Distobuccal, Disto Lingual, Mid Lingual and Mesio Lingual. The longitudinal course will be characterized with respect to the categorical outcome, presence of any bleeding on probing, with initial emphasis being placed upon transition approaches, with specific attention given to shifts from clinically unacceptable to clinically acceptable designations.
probing depth is considered variable from one person to the other however a decrease or a shallower probing depth overtime is gererally seen as an improvement , thus any decrease in probing depth would be seen as signs of healing.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Peri-implant Mucositis</condition>
  <arm_group>
    <arm_group_label>Simvastatin group (Treatment)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Will receive 0.1 ml prepared Simvastatin in 1.2% (W/V) Lecithin/isopropyl palmitate solution (Lipoil速), Poloxamer 407 gel (Polox Gel 20%速) applied topically into the peri-implant gingival sulcus using a plastic syringe with a blunt cannula.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Will receive a placebo of 0.1 ml 40% (W/V) Lecithin/isopropyl palmitate solution (Lipoil速), Poloxamer 407 gel (Polox Gel 20%速) applied topically into the peri-implant gingival sulcus using a plastic syringe with a blunt cannula.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>One topical application in peri-implant gingival crevice</description>
    <arm_group_label>Simvastatin group (Treatment)</arm_group_label>
    <other_name>Simvastatin Powder U.S.P.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One topical application in peri-implant gingival crevice</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>Lecithin/isopropyl palmitate solution, Poloxamer 407 gel</other_name>
    <other_name>Lipoil速, Polox Gel 20%速</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Read, understand, and sign the informed consent forms

          -  Have at least 1 dental implant

          -  Have no evidence of peri-implantitis as evidenced by mesial and distal bone loss more
             than 1 mm from the accepted reference point round the implants on the periapical
             radiograph

          -  Demonstrate peri-implant mucositis as evidenced by bleeding on probing with 0.25 N/cm

        Exclusion Criteria:

          -  Have allergic reactions to simvastatin

          -  Have peri-implantitis as evidenced by more than 1 mm of mesial and distal bone loss
             from an accepted reference point on the implants on the periapical radiograph

          -  Demonstrate no bleeding on probing with 0.25 N/ cm

          -  Have uncontrolled systemic disease

          -  Pregnancy or females who suspect/may be pregnant, as well as nursing and breast
             feeding mothers

          -  Take statin / HMG-CoA reductase inhibitor medications

          -  Smokers

          -  Require antibiotic prophylaxis

          -  Take anti-inflammatory medication, immunosuppressive medications or immunosuppressed
             patients

          -  Have paraben allergies

          -  Have soybean allergies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed M Mahrous, B.D.S., M.S.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa College of Dentistry and Dental Clinics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Iowa College of Dentistry and Dental Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Pradeep AR, Thorat MS. Clinical effect of subgingivally delivered simvastatin in the treatment of patients with chronic periodontitis: a randomized clinical trial. J Periodontol. 2010 Feb;81(2):214-22. doi: 10.1902/jop.2009.090429.</citation>
    <PMID>20151799</PMID>
  </reference>
  <reference>
    <citation>Liskmann S, Vihalemm T, Salum O, Zilmer K, Fischer K, Zilmer M. Correlations between clinical parameters and interleukin-6 and interleukin-10 levels in saliva from totally edentulous patients with peri-implant disease. Int J Oral Maxillofac Implants. 2006 Jul-Aug;21(4):543-50.</citation>
    <PMID>16955604</PMID>
  </reference>
  <reference>
    <citation>Konttinen YT, Lappalainen R, Laine P, Kitti U, Santavirta S, Teronen O. Immunohistochemical evaluation of inflammatory mediators in failing implants. Int J Periodontics Restorative Dent. 2006 Apr;26(2):135-41.</citation>
    <PMID>16642902</PMID>
  </reference>
  <reference>
    <citation>Sakoda K, Yamamoto M, Negishi Y, Liao JK, Node K, Izumi Y. Simvastatin decreases IL-6 and IL-8 production in epithelial cells. J Dent Res. 2006 Jun;85(6):520-3.</citation>
    <PMID>16723648</PMID>
  </reference>
  <reference>
    <citation>G端nc端 GN, Akman AC, G端nday S, Yamal脹k N, Berker E. Effect of inflammation on cytokine levels and bone remodelling markers in peri-implant sulcus fluid: a preliminary report. Cytokine. 2012 Aug;59(2):313-6. doi: 10.1016/j.cyto.2012.04.024. Epub 2012 May 14.</citation>
    <PMID>22592038</PMID>
  </reference>
  <reference>
    <citation>Duarte PM, de Mendon巽a AC, M叩ximo MB, Santos VR, Bastos MF, Nociti J炭nior FH. Differential cytokine expressions affect the severity of peri-implant disease. Clin Oral Implants Res. 2009 May;20(5):514-20. doi: 10.1111/j.1600-0501.2008.01680.x. Epub 2009 Mar 11.</citation>
    <PMID>19302394</PMID>
  </reference>
  <reference>
    <citation>Ferro D, Parrotto S, Basili S, Alessandri C, Violi F. Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. J Am Coll Cardiol. 2000 Aug;36(2):427-31.</citation>
    <PMID>10933353</PMID>
  </reference>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>January 2, 2018</study_first_submitted>
  <study_first_submitted_qc>January 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 17, 2018</study_first_posted>
  <results_first_submitted>March 8, 2018</results_first_submitted>
  <results_first_submitted_qc>October 30, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 29, 2018</results_first_posted>
  <last_update_submitted>November 28, 2018</last_update_submitted>
  <last_update_submitted_qc>November 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Ahmed Mohamed Mahrous</investigator_full_name>
    <investigator_title>Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>topical</keyword>
  <keyword>subgingival</keyword>
  <keyword>simvastatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucositis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 30, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/75/NCT03400475/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Test Group</title>
          <description>Will receive 0.1 ml prepared Simvastatin in 1.2% (W/V) Lecithin/isopropyl palmitate solution (Lipoil速), Poloxamer 407 gel (Polox Gel 20%速) applied topically into the peri-implant gingival sulcus using a plastic syringe with a blunt cannula.
Simvastatin: One topical application in peri-implant gingival crevice</description>
        </group>
        <group group_id="P2">
          <title>Control Group</title>
          <description>Will receive a placebo of 0.1 ml 40% (W/V) Lecithin/isopropyl palmitate solution (Lipoil速), Poloxamer 407 gel (Polox Gel 20%速) applied topically into the peri-implant gingival sulcus using a plastic syringe with a blunt cannula.
Placebo: One topical application in peri-implant gingival crevice</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>each patient is considered one unit</population>
      <group_list>
        <group group_id="B1">
          <title>Test Group</title>
          <description>Will receive 0.1 ml prepared Simvastatin in 1.2% (W/V) Lecithin/isopropyl palmitate solution (Lipoil速), Poloxamer 407 gel (Polox Gel 20%速) applied topically into the peri-implant gingival sulcus using a plastic syringe with a blunt cannula.
Simvastatin: One topical application in peri-implant gingival crevice</description>
        </group>
        <group group_id="B2">
          <title>Control Group</title>
          <description>Will receive a placebo of 0.1 ml 40% (W/V) Lecithin/isopropyl palmitate solution (Lipoil速), Poloxamer 407 gel (Polox Gel 20%速) applied topically into the peri-implant gingival sulcus using a plastic syringe with a blunt cannula.
Placebo: One topical application in peri-implant gingival crevice</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="46"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.45" spread="13.3"/>
                    <measurement group_id="B2" value="63.1" spread="14.3"/>
                    <measurement group_id="B3" value="63.3" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Interleukin 1 B at Base to 24 Hours</title>
        <description>Measuring the change in Cytokine levels in the peri implant crevicular fluid ( Fluid around the implant) by extracting the fluid and measuring the levels of the interlukins in the fluids in Micrograms per dicileter ( ug/dl)</description>
        <time_frame>Baseline- 24hrs</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin Group ( Treatment )</title>
            <description>Will receive 0.1 ml prepared Simvastatin in 1.2% (W/V) Lecithin/isopropyl palmitate solution (Lipoil速), Poloxamer 407 gel (Polox Gel 20%速) applied topically into the peri-implant gingival sulcus using a plastic syringe with a blunt cannula.
Simvastatin: One topical application in peri-implant gingival crevice</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Will receive a placebo of 0.1 ml 40% (W/V) Lecithin/isopropyl palmitate solution (Lipoil速), Poloxamer 407 gel (Polox Gel 20%速) applied topically into the peri-implant gingival sulcus using a plastic syringe with a blunt cannula.
Placebo: One topical application in peri-implant gingival crevice</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Interleukin 1 B at Base to 24 Hours</title>
          <description>Measuring the change in Cytokine levels in the peri implant crevicular fluid ( Fluid around the implant) by extracting the fluid and measuring the levels of the interlukins in the fluids in Micrograms per dicileter ( ug/dl)</description>
          <units>Micrograms per deciliter (ug/dl)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.075" spread="15.587"/>
                    <measurement group_id="O2" value="1.013" spread="5.273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.90</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.088</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Interleukin 1 B at Base to 1 Week</title>
        <description>Measuring the change in Cytokine levels in the peri implant crevicular fluid ( Fluid around the implant) by extracting the fluid and measuring the levels of the interlukins in the fluids in Micrograms per dicileter ( ug/dl)</description>
        <time_frame>Baseline - 1 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin Group ( Treatment )</title>
            <description>Will receive 0.1 ml prepared Simvastatin in 1.2% (W/V) Lecithin/isopropyl palmitate solution (Lipoil速), Poloxamer 407 gel (Polox Gel 20%速) applied topically into the peri-implant gingival sulcus using a plastic syringe with a blunt cannula.
Simvastatin: One topical application in peri-implant gingival crevice</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Will receive a placebo of 0.1 ml 40% (W/V) Lecithin/isopropyl palmitate solution (Lipoil速), Poloxamer 407 gel (Polox Gel 20%速) applied topically into the peri-implant gingival sulcus using a plastic syringe with a blunt cannula.
Placebo: One topical application in peri-implant gingival crevice</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Interleukin 1 B at Base to 1 Week</title>
          <description>Measuring the change in Cytokine levels in the peri implant crevicular fluid ( Fluid around the implant) by extracting the fluid and measuring the levels of the interlukins in the fluids in Micrograms per dicileter ( ug/dl)</description>
          <units>Micrograms per deciliter (ug/dl)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5016" spread="15.4701"/>
                    <measurement group_id="O2" value="-1.095" spread="8.6050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.90</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.59</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Interleukin 1 B 24 Hours - 1 Week</title>
        <description>Measuring the change in Cytokine levels in the peri implant crevicular fluid ( Fluid around the implant) by extracting the fluid and measuring the levels of the interlukins in the fluids in Micrograms per dicileter ( ug/dl)</description>
        <time_frame>24 hours - 1 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin Group ( Treatment )</title>
            <description>Will receive 0.1 ml prepared Simvastatin in 1.2% (W/V) Lecithin/isopropyl palmitate solution (Lipoil速), Poloxamer 407 gel (Polox Gel 20%速) applied topically into the peri-implant gingival sulcus using a plastic syringe with a blunt cannula.
Simvastatin: One topical application in peri-implant gingival crevice</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Will receive a placebo of 0.1 ml 40% (W/V) Lecithin/isopropyl palmitate solution (Lipoil速), Poloxamer 407 gel (Polox Gel 20%速) applied topically into the peri-implant gingival sulcus using a plastic syringe with a blunt cannula.
Placebo: One topical application in peri-implant gingival crevice</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Interleukin 1 B 24 Hours - 1 Week</title>
          <description>Measuring the change in Cytokine levels in the peri implant crevicular fluid ( Fluid around the implant) by extracting the fluid and measuring the levels of the interlukins in the fluids in Micrograms per dicileter ( ug/dl)</description>
          <units>Micrograms per deciliter (ug/dl)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.577" spread="14.137"/>
                    <measurement group_id="O2" value="-2.108" spread="10.569"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.90</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.596</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Interleukin 6 at Base to 24 Hours</title>
        <description>Measuring the change in Cytokine levels in the peri implant crevicular fluid ( Fluid around the implant) by extracting the fluid and measuring the levels of the interlukins in the fluids in Micrograms per dicileter ( ug/dl)</description>
        <time_frame>Baseline - 24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin Group ( Treatment )</title>
            <description>Will receive 0.1 ml prepared Simvastatin in 1.2% (W/V) Lecithin/isopropyl palmitate solution (Lipoil速), Poloxamer 407 gel (Polox Gel 20%速) applied topically into the peri-implant gingival sulcus using a plastic syringe with a blunt cannula.
Simvastatin: One topical application in peri-implant gingival crevice</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Will receive a placebo of 0.1 ml 40% (W/V) Lecithin/isopropyl palmitate solution (Lipoil速), Poloxamer 407 gel (Polox Gel 20%速) applied topically into the peri-implant gingival sulcus using a plastic syringe with a blunt cannula.
Placebo: One topical application in peri-implant gingival crevice</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Interleukin 6 at Base to 24 Hours</title>
          <description>Measuring the change in Cytokine levels in the peri implant crevicular fluid ( Fluid around the implant) by extracting the fluid and measuring the levels of the interlukins in the fluids in Micrograms per dicileter ( ug/dl)</description>
          <units>Micrograms per deciliter (ug/dl)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.118" spread="0.954"/>
                    <measurement group_id="O2" value="0.201" spread="0.880"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.90</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.083</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Interleukin 6 Baseline to 1 Week</title>
        <description>Measuring the change in Cytokine levels in the peri implant crevicular fluid ( Fluid around the implant) by extracting the fluid and measuring the levels of the interlukins in the fluids in Micrograms per dicileter ( ug/dl)</description>
        <time_frame>Baseline - 1 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin Group ( Treatment )</title>
            <description>Will receive 0.1 ml prepared Simvastatin in 1.2% (W/V) Lecithin/isopropyl palmitate solution (Lipoil速), Poloxamer 407 gel (Polox Gel 20%速) applied topically into the peri-implant gingival sulcus using a plastic syringe with a blunt cannula.
Simvastatin: One topical application in peri-implant gingival crevice</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Will receive a placebo of 0.1 ml 40% (W/V) Lecithin/isopropyl palmitate solution (Lipoil速), Poloxamer 407 gel (Polox Gel 20%速) applied topically into the peri-implant gingival sulcus using a plastic syringe with a blunt cannula.
Placebo: One topical application in peri-implant gingival crevice</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Interleukin 6 Baseline to 1 Week</title>
          <description>Measuring the change in Cytokine levels in the peri implant crevicular fluid ( Fluid around the implant) by extracting the fluid and measuring the levels of the interlukins in the fluids in Micrograms per dicileter ( ug/dl)</description>
          <units>Micrograms per deciliter (ug/dl)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.304" spread="1.3744"/>
                    <measurement group_id="O2" value="0.275" spread="1.296"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.90</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.581</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Interleukin 6 24 Hours - 1 Week</title>
        <description>Measuring the change in Cytokine levels in the peri implant crevicular fluid ( Fluid around the implant) by extracting the fluid and measuring the levels of the interlukins in the fluids in Micrograms per dicileter ( ug/dl)</description>
        <time_frame>24 hours - 1 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin Group ( Treatment )</title>
            <description>Will receive 0.1 ml prepared Simvastatin in 1.2% (W/V) Lecithin/isopropyl palmitate solution (Lipoil速), Poloxamer 407 gel (Polox Gel 20%速) applied topically into the peri-implant gingival sulcus using a plastic syringe with a blunt cannula.
Simvastatin: One topical application in peri-implant gingival crevice</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Will receive a placebo of 0.1 ml 40% (W/V) Lecithin/isopropyl palmitate solution (Lipoil速), Poloxamer 407 gel (Polox Gel 20%速) applied topically into the peri-implant gingival sulcus using a plastic syringe with a blunt cannula.
Placebo: One topical application in peri-implant gingival crevice</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Interleukin 6 24 Hours - 1 Week</title>
          <description>Measuring the change in Cytokine levels in the peri implant crevicular fluid ( Fluid around the implant) by extracting the fluid and measuring the levels of the interlukins in the fluids in Micrograms per dicileter ( ug/dl)</description>
          <units>Micrograms per deciliter (ug/dl)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.185" spread="2.039"/>
                    <measurement group_id="O2" value="0.073" spread="1.522"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.90</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.029</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Interleukin 8 at Base to 24 Hours</title>
        <description>Measuring the change in Cytokine levels in the peri implant crevicular fluid ( Fluid around the implant) by extracting the fluid and measuring the levels of the interlukins in the fluids in Micrograms per dicileter ( ug/dl)</description>
        <time_frame>Baseline - 24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin Group ( Treatment )</title>
            <description>Will receive 0.1 ml prepared Simvastatin in 1.2% (W/V) Lecithin/isopropyl palmitate solution (Lipoil速), Poloxamer 407 gel (Polox Gel 20%速) applied topically into the peri-implant gingival sulcus using a plastic syringe with a blunt cannula.
Simvastatin: One topical application in peri-implant gingival crevice</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Will receive a placebo of 0.1 ml 40% (W/V) Lecithin/isopropyl palmitate solution (Lipoil速), Poloxamer 407 gel (Polox Gel 20%速) applied topically into the peri-implant gingival sulcus using a plastic syringe with a blunt cannula.
Placebo: One topical application in peri-implant gingival crevice</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Interleukin 8 at Base to 24 Hours</title>
          <description>Measuring the change in Cytokine levels in the peri implant crevicular fluid ( Fluid around the implant) by extracting the fluid and measuring the levels of the interlukins in the fluids in Micrograms per dicileter ( ug/dl)</description>
          <units>Micrograms per deciliter (ug/dl)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="331.021"/>
                    <measurement group_id="O2" value="64.696" spread="197.902"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.86</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-64.696</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Interleukin 8 at Base to 1 Week</title>
        <description>Measuring the change in Cytokine levels in the peri implant crevicular fluid ( Fluid around the implant) by extracting the fluid and measuring the levels of the interlukins in the fluids in Micrograms per dicileter ( ug/dl)</description>
        <time_frame>Baseline - 1 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin Group ( Treatment )</title>
            <description>Will receive 0.1 ml prepared Simvastatin in 1.2% (W/V) Lecithin/isopropyl palmitate solution (Lipoil速), Poloxamer 407 gel (Polox Gel 20%速) applied topically into the peri-implant gingival sulcus using a plastic syringe with a blunt cannula.
Simvastatin: One topical application in peri-implant gingival crevice</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Will receive a placebo of 0.1 ml 40% (W/V) Lecithin/isopropyl palmitate solution (Lipoil速), Poloxamer 407 gel (Polox Gel 20%速) applied topically into the peri-implant gingival sulcus using a plastic syringe with a blunt cannula.
Placebo: One topical application in peri-implant gingival crevice</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Interleukin 8 at Base to 1 Week</title>
          <description>Measuring the change in Cytokine levels in the peri implant crevicular fluid ( Fluid around the implant) by extracting the fluid and measuring the levels of the interlukins in the fluids in Micrograms per dicileter ( ug/dl)</description>
          <units>Micrograms per deciliter (ug/dl)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131.368" spread="480.835"/>
                    <measurement group_id="O2" value="20.275" spread="389.666"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.86</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>111.03</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Interleukin 8 24 Hours to 1 Week</title>
        <description>Measuring the change in Cytokine levels in the peri implant crevicular fluid ( Fluid around the implant) by extracting the fluid and measuring the levels of the interlukins in the fluids in Micrograms per dicileter ( ug/dl)</description>
        <time_frame>24 hours - 1 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin Group ( Treatment )</title>
            <description>Will receive 0.1 ml prepared Simvastatin in 1.2% (W/V) Lecithin/isopropyl palmitate solution (Lipoil速), Poloxamer 407 gel (Polox Gel 20%速) applied topically into the peri-implant gingival sulcus using a plastic syringe with a blunt cannula.
Simvastatin: One topical application in peri-implant gingival crevice</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Will receive a placebo of 0.1 ml 40% (W/V) Lecithin/isopropyl palmitate solution (Lipoil速), Poloxamer 407 gel (Polox Gel 20%速) applied topically into the peri-implant gingival sulcus using a plastic syringe with a blunt cannula.
Placebo: One topical application in peri-implant gingival crevice</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Interleukin 8 24 Hours to 1 Week</title>
          <description>Measuring the change in Cytokine levels in the peri implant crevicular fluid ( Fluid around the implant) by extracting the fluid and measuring the levels of the interlukins in the fluids in Micrograms per dicileter ( ug/dl)</description>
          <units>Micrograms per deciliter (ug/dl)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168.894" spread="548.154"/>
                    <measurement group_id="O2" value="-44.42" spread="484.019"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.86</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>213.314</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Tumor Necrosis Factor Alpha at Base to 24 Hours</title>
        <description>Measuring the change in Cytokine levels in the peri implant crevicular fluid ( Fluid around the implant) by extracting the fluid and measuring the levels of the interlukins in the fluids in Micrograms per dicileter ( ug/dl)</description>
        <time_frame>Baseline- 24hrs</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin Group ( Treatment )</title>
            <description>Will receive 0.1 ml prepared Simvastatin in 1.2% (W/V) Lecithin/isopropyl palmitate solution (Lipoil速), Poloxamer 407 gel (Polox Gel 20%速) applied topically into the peri-implant gingival sulcus using a plastic syringe with a blunt cannula.
Simvastatin: One topical application in peri-implant gingival crevice</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Will receive a placebo of 0.1 ml 40% (W/V) Lecithin/isopropyl palmitate solution (Lipoil速), Poloxamer 407 gel (Polox Gel 20%速) applied topically into the peri-implant gingival sulcus using a plastic syringe with a blunt cannula.
Placebo: One topical application in peri-implant gingival crevice</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Tumor Necrosis Factor Alpha at Base to 24 Hours</title>
          <description>Measuring the change in Cytokine levels in the peri implant crevicular fluid ( Fluid around the implant) by extracting the fluid and measuring the levels of the interlukins in the fluids in Micrograms per dicileter ( ug/dl)</description>
          <units>Micrograms per deciliter (ug/dl)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.526" spread="1.266"/>
                    <measurement group_id="O2" value="-0.17" spread="1.589"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.41</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>37.356</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Tumor Necrosis Factor Alpha at Base to 1 Week</title>
        <description>Measuring the change in Cytokine levels in the peri implant crevicular fluid ( Fluid around the implant) by extracting the fluid and measuring the levels of the interlukins in the fluids in Micrograms per dicileter ( ug/dl)</description>
        <time_frame>Baseline - 1 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin Group ( Treatment )</title>
            <description>Will receive 0.1 ml prepared Simvastatin in 1.2% (W/V) Lecithin/isopropyl palmitate solution (Lipoil速), Poloxamer 407 gel (Polox Gel 20%速) applied topically into the peri-implant gingival sulcus using a plastic syringe with a blunt cannula.
Simvastatin: One topical application in peri-implant gingival crevice</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Will receive a placebo of 0.1 ml 40% (W/V) Lecithin/isopropyl palmitate solution (Lipoil速), Poloxamer 407 gel (Polox Gel 20%速) applied topically into the peri-implant gingival sulcus using a plastic syringe with a blunt cannula.
Placebo: One topical application in peri-implant gingival crevice</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Tumor Necrosis Factor Alpha at Base to 1 Week</title>
          <description>Measuring the change in Cytokine levels in the peri implant crevicular fluid ( Fluid around the implant) by extracting the fluid and measuring the levels of the interlukins in the fluids in Micrograms per dicileter ( ug/dl)</description>
          <units>Micrograms per deciliter (ug/dl)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5833" spread="5.665"/>
                    <measurement group_id="O2" value="-0.0704" spread="2.8536401"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.41</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.6537</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Tumor Necrosis Factor Alpha 24 Hours to 1 Week</title>
        <description>Measuring the change in Cytokine levels in the peri implant crevicular fluid ( Fluid around the implant) by extracting the fluid and measuring the levels of the interlukins in the fluids in Micrograms per dicileter ( ug/dl)</description>
        <time_frame>24hrs - 1 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin Group ( Treatment )</title>
            <description>Will receive 0.1 ml prepared Simvastatin in 1.2% (W/V) Lecithin/isopropyl palmitate solution (Lipoil速), Poloxamer 407 gel (Polox Gel 20%速) applied topically into the peri-implant gingival sulcus using a plastic syringe with a blunt cannula.
Simvastatin: One topical application in peri-implant gingival crevice</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Will receive a placebo of 0.1 ml 40% (W/V) Lecithin/isopropyl palmitate solution (Lipoil速), Poloxamer 407 gel (Polox Gel 20%速) applied topically into the peri-implant gingival sulcus using a plastic syringe with a blunt cannula.
Placebo: One topical application in peri-implant gingival crevice</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Tumor Necrosis Factor Alpha 24 Hours to 1 Week</title>
          <description>Measuring the change in Cytokine levels in the peri implant crevicular fluid ( Fluid around the implant) by extracting the fluid and measuring the levels of the interlukins in the fluids in Micrograms per dicileter ( ug/dl)</description>
          <units>Micrograms per deciliter (ug/dl)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.641" spread="5.7217"/>
                    <measurement group_id="O2" value="0.095" spread="3.633"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.41</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.552</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gingival Index Level (Derived From an Average Over the 4 Implant Sites) at Baseline</title>
        <description>Using the Gingival index by Loe and Sillness 1963, the inflammatory state of the Buccal, Lingual, Mesial and Distal Surfaces of the gingiva will be scored using the following score system:
0= normal gingival without signs of inflammation, no inflammation, no bleeding
minor inflammation , slight discoloration, minor surface alterations, no bleeding
moderate inflammation, redness, swelling, bleeding upon probing and under pressure
strong inflammation, strong redness and swelling, tendency toward spontaneous bleeding, ulcerations After a score is given to each site the scores are summed together and divided by 4 to reach an overall score.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin Group ( Treatment)</title>
            <description>Will receive 0.1 ml prepared Simvastatin in 1.2% (W/V) Lecithin/isopropyl palmitate solution (Lipoil速), Poloxamer 407 gel (Polox Gel 20%速) applied topically into the peri-implant gingival sulcus using a plastic syringe with a blunt cannula.
Simvastatin: One topical application in peri-implant gingival crevice</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Will receive a placebo of 0.1 ml 40% (W/V) Lecithin/isopropyl palmitate solution (Lipoil速), Poloxamer 407 gel (Polox Gel 20%速) applied topically into the peri-implant gingival sulcus using a plastic syringe with a blunt cannula.
Placebo: One topical application in peri-implant gingival crevice</description>
          </group>
        </group_list>
        <measure>
          <title>Gingival Index Level (Derived From an Average Over the 4 Implant Sites) at Baseline</title>
          <description>Using the Gingival index by Loe and Sillness 1963, the inflammatory state of the Buccal, Lingual, Mesial and Distal Surfaces of the gingiva will be scored using the following score system:
0= normal gingival without signs of inflammation, no inflammation, no bleeding
minor inflammation , slight discoloration, minor surface alterations, no bleeding
moderate inflammation, redness, swelling, bleeding upon probing and under pressure
strong inflammation, strong redness and swelling, tendency toward spontaneous bleeding, ulcerations After a score is given to each site the scores are summed together and divided by 4 to reach an overall score.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Gingival index score of 0.50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gingival index score of 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gingival index score of 1.25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gingival index score of 1.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gingival index score of 1.75</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.071</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gingival Index Level (Derived From an Average Over the 4 Implant Sites) at 24 Hours</title>
        <description>Using the Gingival index by Loe and Sillness 1963, the inflammatory state of the Buccal, Lingual, Mesial and Distal Surfaces of the gingiva will be scored using the following score system:
0= normal gingival without signs of inflammation, no inflammation, no bleeding
minor inflammation , slight discoloration, minor surface alterations, no bleeding
moderate inflammation, redness, swelling, bleeding upon probing and under pressure
strong inflammation, strong redness and swelling, tendency toward spontaneous bleeding, ulcerations After a score is given to each site the scores are summed together and divided by 4 to reach an overall score.</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin Group ( Treatment)</title>
            <description>Will receive 0.1 ml prepared Simvastatin in 1.2% (W/V) Lecithin/isopropyl palmitate solution (Lipoil速), Poloxamer 407 gel (Polox Gel 20%速) applied topically into the peri-implant gingival sulcus using a plastic syringe with a blunt cannula.
Simvastatin: One topical application in peri-implant gingival crevice</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Will receive a placebo of 0.1 ml 40% (W/V) Lecithin/isopropyl palmitate solution (Lipoil速), Poloxamer 407 gel (Polox Gel 20%速) applied topically into the peri-implant gingival sulcus using a plastic syringe with a blunt cannula.
Placebo: One topical application in peri-implant gingival crevice</description>
          </group>
        </group_list>
        <measure>
          <title>Gingival Index Level (Derived From an Average Over the 4 Implant Sites) at 24 Hours</title>
          <description>Using the Gingival index by Loe and Sillness 1963, the inflammatory state of the Buccal, Lingual, Mesial and Distal Surfaces of the gingiva will be scored using the following score system:
0= normal gingival without signs of inflammation, no inflammation, no bleeding
minor inflammation , slight discoloration, minor surface alterations, no bleeding
moderate inflammation, redness, swelling, bleeding upon probing and under pressure
strong inflammation, strong redness and swelling, tendency toward spontaneous bleeding, ulcerations After a score is given to each site the scores are summed together and divided by 4 to reach an overall score.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Gingival sscore of 0.50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gingival sscore of 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gingival sscore of 1.25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gingival sscore of 1.50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gingival sscore of 1.75</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.071</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gingival Index Level (Derived From an Average Over the 4 Implant Sites) at 1 Week</title>
        <description>Using the Gingival index by Loe and Sillness 1963, the inflammatory state of the Buccal, Lingual, Mesial and Distal Surfaces of the gingiva will be scored using the following score system:
0= normal gingival without signs of inflammation, no inflammation, no bleeding
minor inflammation , slight discoloration, minor surface alterations, no bleeding
moderate inflammation, redness, swelling, bleeding upon probing and under pressure
strong inflammation, strong redness and swelling, tendency toward spontaneous bleeding, ulcerations After a score is given to each site the scores are summed together and divided by 4 to reach an overall score.</description>
        <time_frame>1 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin Group ( Treatment)</title>
            <description>Will receive 0.1 ml prepared Simvastatin in 1.2% (W/V) Lecithin/isopropyl palmitate solution (Lipoil速), Poloxamer 407 gel (Polox Gel 20%速) applied topically into the peri-implant gingival sulcus using a plastic syringe with a blunt cannula.
Simvastatin: One topical application in peri-implant gingival crevice</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Will receive a placebo of 0.1 ml 40% (W/V) Lecithin/isopropyl palmitate solution (Lipoil速), Poloxamer 407 gel (Polox Gel 20%速) applied topically into the peri-implant gingival sulcus using a plastic syringe with a blunt cannula.
Placebo: One topical application in peri-implant gingival crevice</description>
          </group>
        </group_list>
        <measure>
          <title>Gingival Index Level (Derived From an Average Over the 4 Implant Sites) at 1 Week</title>
          <description>Using the Gingival index by Loe and Sillness 1963, the inflammatory state of the Buccal, Lingual, Mesial and Distal Surfaces of the gingiva will be scored using the following score system:
0= normal gingival without signs of inflammation, no inflammation, no bleeding
minor inflammation , slight discoloration, minor surface alterations, no bleeding
moderate inflammation, redness, swelling, bleeding upon probing and under pressure
strong inflammation, strong redness and swelling, tendency toward spontaneous bleeding, ulcerations After a score is given to each site the scores are summed together and divided by 4 to reach an overall score.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Gingival sscore of 0.50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gingival sscore of 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gingival sscore of 1.25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gingival sscore of 1.50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gingival sscore of 1.75</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Probing Depth Level (Averaged Over 6 Sites) at Baseline</title>
        <description>Depth will be measured by a calibrated periodontal probe at 6 different locations, Mesiobuccal, Mid Buccal, Distobuccal, Disto Lingual, Mid Lingual and Mesio Lingual. The longitudinal course will be characterized with respect to the categorical outcome, presence of any bleeding on probing, with initial emphasis being placed upon transition approaches, with specific attention given to shifts from clinically unacceptable to clinically acceptable designations.
probing depth is considered variable from one person to the other however a decrease or a shallower probing depth overtime is gererally seen as an improvement , thus any decrease in probing depth would be seen as signs of healing.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin Group ( Treatment)</title>
            <description>Will receive 0.1 ml prepared Simvastatin in 1.2% (W/V) Lecithin/isopropyl palmitate solution (Lipoil速), Poloxamer 407 gel (Polox Gel 20%速) applied topically into the peri-implant gingival sulcus using a plastic syringe with a blunt cannula.
Simvastatin: One topical application in peri-implant gingival crevice</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Will receive a placebo of 0.1 ml 40% (W/V) Lecithin/isopropyl palmitate solution (Lipoil速), Poloxamer 407 gel (Polox Gel 20%速) applied topically into the peri-implant gingival sulcus using a plastic syringe with a blunt cannula.
Placebo: One topical application in peri-implant gingival crevice</description>
          </group>
        </group_list>
        <measure>
          <title>Probing Depth Level (Averaged Over 6 Sites) at Baseline</title>
          <description>Depth will be measured by a calibrated periodontal probe at 6 different locations, Mesiobuccal, Mid Buccal, Distobuccal, Disto Lingual, Mid Lingual and Mesio Lingual. The longitudinal course will be characterized with respect to the categorical outcome, presence of any bleeding on probing, with initial emphasis being placed upon transition approaches, with specific attention given to shifts from clinically unacceptable to clinically acceptable designations.
probing depth is considered variable from one person to the other however a decrease or a shallower probing depth overtime is gererally seen as an improvement , thus any decrease in probing depth would be seen as signs of healing.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Probing Depth Score 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probing Depth Score 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probing Depth 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probing Depth 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probing Depth 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probing Depth 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.062</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Probing Depth Level (Averaged Over 6 Sites) at 24 Hours</title>
        <description>Depth will be measured by a calibrated periodontal probe at 6 different locations, Mesiobuccal, Mid Buccal, Distobuccal, Disto Lingual, Mid Lingual and Mesio Lingual. The longitudinal course will be characterized with respect to the categorical outcome, presence of any bleeding on probing, with initial emphasis being placed upon transition approaches, with specific attention given to shifts from clinically unacceptable to clinically acceptable designations.
probing depth is considered variable from one person to the other however a decrease or a shallower probing depth overtime is gererally seen as an improvement , thus any decrease in probing depth would be seen as signs of healing.</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin Group ( Treatment)</title>
            <description>Will receive 0.1 ml prepared Simvastatin in 1.2% (W/V) Lecithin/isopropyl palmitate solution (Lipoil速), Poloxamer 407 gel (Polox Gel 20%速) applied topically into the peri-implant gingival sulcus using a plastic syringe with a blunt cannula.
Simvastatin: One topical application in peri-implant gingival crevice</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Will receive a placebo of 0.1 ml 40% (W/V) Lecithin/isopropyl palmitate solution (Lipoil速), Poloxamer 407 gel (Polox Gel 20%速) applied topically into the peri-implant gingival sulcus using a plastic syringe with a blunt cannula.
Placebo: One topical application in peri-implant gingival crevice</description>
          </group>
        </group_list>
        <measure>
          <title>Probing Depth Level (Averaged Over 6 Sites) at 24 Hours</title>
          <description>Depth will be measured by a calibrated periodontal probe at 6 different locations, Mesiobuccal, Mid Buccal, Distobuccal, Disto Lingual, Mid Lingual and Mesio Lingual. The longitudinal course will be characterized with respect to the categorical outcome, presence of any bleeding on probing, with initial emphasis being placed upon transition approaches, with specific attention given to shifts from clinically unacceptable to clinically acceptable designations.
probing depth is considered variable from one person to the other however a decrease or a shallower probing depth overtime is gererally seen as an improvement , thus any decrease in probing depth would be seen as signs of healing.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Probing Depth Score 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probing Depth Score 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probing Depth 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probing Depth 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probing Depth 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probing Depth 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.54</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Probing Depth Level (Averaged Over 6 Sites) at 1 Week</title>
        <description>Depth will be measured by a calibrated periodontal probe at 6 different locations, Mesiobuccal, Mid Buccal, Distobuccal, Disto Lingual, Mid Lingual and Mesio Lingual. The longitudinal course will be characterized with respect to the categorical outcome, presence of any bleeding on probing, with initial emphasis being placed upon transition approaches, with specific attention given to shifts from clinically unacceptable to clinically acceptable designations.
probing depth is considered variable from one person to the other however a decrease or a shallower probing depth overtime is gererally seen as an improvement , thus any decrease in probing depth would be seen as signs of healing.</description>
        <time_frame>1 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin Group ( Treatment)</title>
            <description>Will receive 0.1 ml prepared Simvastatin in 1.2% (W/V) Lecithin/isopropyl palmitate solution (Lipoil速), Poloxamer 407 gel (Polox Gel 20%速) applied topically into the peri-implant gingival sulcus using a plastic syringe with a blunt cannula.
Simvastatin: One topical application in peri-implant gingival crevice</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Will receive a placebo of 0.1 ml 40% (W/V) Lecithin/isopropyl palmitate solution (Lipoil速), Poloxamer 407 gel (Polox Gel 20%速) applied topically into the peri-implant gingival sulcus using a plastic syringe with a blunt cannula.
Placebo: One topical application in peri-implant gingival crevice</description>
          </group>
        </group_list>
        <measure>
          <title>Probing Depth Level (Averaged Over 6 Sites) at 1 Week</title>
          <description>Depth will be measured by a calibrated periodontal probe at 6 different locations, Mesiobuccal, Mid Buccal, Distobuccal, Disto Lingual, Mid Lingual and Mesio Lingual. The longitudinal course will be characterized with respect to the categorical outcome, presence of any bleeding on probing, with initial emphasis being placed upon transition approaches, with specific attention given to shifts from clinically unacceptable to clinically acceptable designations.
probing depth is considered variable from one person to the other however a decrease or a shallower probing depth overtime is gererally seen as an improvement , thus any decrease in probing depth would be seen as signs of healing.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Probing Depth Score 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probing Depth Score 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probing Depth 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probing Depth 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probing Depth 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probing Depth 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.34</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Test Group</title>
          <description>Will receive 0.1 ml prepared Simvastatin in 1.2% (W/V) Lecithin/isopropyl palmitate solution (Lipoil速), Poloxamer 407 gel (Polox Gel 20%速) applied topically into the peri-implant gingival sulcus using a plastic syringe with a blunt cannula.
Simvastatin: One topical application in peri-implant gingival crevice</description>
        </group>
        <group group_id="E2">
          <title>Control Group</title>
          <description>Will receive a placebo of 0.1 ml 40% (W/V) Lecithin/isopropyl palmitate solution (Lipoil速), Poloxamer 407 gel (Polox Gel 20%速) applied topically into the peri-implant gingival sulcus using a plastic syringe with a blunt cannula.
Placebo: One topical application in peri-implant gingival crevice</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ahmed Mahrous</name_or_title>
      <organization>University of Iowa</organization>
      <phone>3193336517</phone>
      <email>ahmedmohamed-mahrous@uiowa.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

